Recent Updates
Recently added Catalysts

Xerostomia: one US-listed biotech with a clinical-stage programme

Immunology & InflammationUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$1.3Buniverse median $1.20B
Allocated capital$671M$1.3B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank182/299crowding rank 193

Xerostomia is uncontested. MeiraGTx Holdings (MGTX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with AAV2-hAQP1 Concentration 1 in phase 2.

There is no public comparable to price it against. MGTX spreads its $1.3B market cap across 2 indications, so $671M of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$671M of allocated capital sits in Xerostomia, ranking it 182nd of 299 indications by the money committed to it.

Companies developing drugs for Xerostomia 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
MGTXMeiraGTx HoldingsAAV2-hAQP1 Concentration 1Phase 22$1.3BNo2 30 Jun 2027

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Xerostomia counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Xerostomia has one competitor and a median of $1.3B.

Immunology & Inflammation

Immunology & Inflammation holds $139B of the map's capital, 20.7% of the total, spread across 51 indications and 82 companies. 23 of those indications have more than one company competing.

See every Immunology & Inflammation indication on the map

Related indications in Immunology & Inflammation

Chronic Granulomatous Disease1 company · $673M · median $673MUncontestedAcne1 company · $673M · median $673MUncontestedPsoriatic Arthritis1 company · $646M · median $1.3BUncontestedInflammatory Bowel Disease1 company · $609M · median $3.0BUncontestedLupus Nephritis5 companies · $589M · median $516MOrphan cornerSystemic Sclerosis4 companies · $582M · median $540MOrphan cornerCeliac Disease1 company · $788M · median $1.6BUncontestedIgG4 Related Disease1 company · $536M · median $2.1BUncontested

Xerostomia pipeline questions

Which biotech companies are developing drugs for Xerostomia?

MeiraGTx Holdings (MGTX, AAV2-hAQP1 Concentration 1, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Xerostomia.

How advanced is the Xerostomia pipeline?

Of the 1 clinical-stage programme in Xerostomia, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Xerostomia?

No. MGTX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Xerostomia, which is why the indication is classified as uncontested.

When is the next Xerostomia catalyst?

The next dated catalyst in Xerostomia is MGTX on 30 Jun 2027. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map